Since its deployment in December 2020, the U.S. SARS-CoV-2 Serology Standard has been adopted by laboratories near and far.
As of September 15, 2021, there had been 84 requests for the standard from the pharmaceutical industry, U.S. government researchers, the National Cancer Institute's Serological Sciences Network (SeroNet), academic institutions, and other groups—both in the U.S. and internationally. The accompanying evaluation panel has been shared with more than 19 organizations.
The standard is calibrated against the World Health Organization International Standard. It is available free of charge to any laboratory studying SARS-CoV-2 serology.
“If you are doing serology assays, we would be happy to provide you with the standard and with one-on-one guidance on how to use it,” said Ligia Pinto, Ph.D., the director of the Vaccine, Immunity, and Cancer Directorate at the Frederick National Laboratory, who co-chairs the Clinical and Translational Serology Task Force and coordinates SeroNet.
Groups that aren’t members of SeroNet can request the standard via the Serology Standard page.